Pure Global AI
NCT05774873Not yet recruiting

IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

A Phase 1 Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Solid Tumors
Drug/Device/Intervention
IBI334
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Location
Waratah, Australia
Timeline & enrollment
Phase
Phase 1
Start date
Jul 31, 2023
End date
Jun 30, 2026
Enrollment
128 participants
Primary outcome

Number of patients with treatment-related adverse events,Percentage of subjects woth Dose-Limitine toxicities(DLTs)

Summary

The primary objective of this study to evaluate the safety and tolerability of IBI334 and
 determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI334.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm of other connective and soft tissueCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Parametrium
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05774873
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05774873 through Pure Global AI's free database. This Phase 1 trial is sponsored by Innovent Biologics (Suzhou) Co. Ltd. and is currently Not yet recruiting. The study focuses on Solid Tumors. Target enrollment is 128 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.